BC Week In Review | Feb 10, 2014
Company News

Medicines Co., U.S. Department of Health and Human Services (HHS) infectious news

HHS's Biomedical Advanced Research and Development Agency awarded The Medicines Co. a contract worth up to $90 million to develop Carbavance for serious Gram-negative infections as well as melioidosis and glanders, which are caused by...
BC Extra | Feb 6, 2014
Company News

BARDA awards MDCO up to $90M for Carbavance

HHS's Biomedical Advanced Research and Development Agency awarded The Medicines Co. (NASDAQ:MDCO) a contract worth up to $90 million to develop Carbavance for serious gram-negative infections as well as melioidosis and glanders, which are caused...
BC Week In Review | Jan 20, 2014
Clinical News

Carbavance regulatory update

The Medicines Co. said FDA granted Qualified Infectious Disease Product (QIDP) designation for Carbavance in 6 indications, including complicated urinary tract infections (cUTIs), complicated intra-abdominal infections (cIAIs), hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) and febrile neutropenia. The...
BC Week In Review | Dec 9, 2013
Company News

Rempex Pharmaceuticals, Medicines Co. deal

The Medicines Co. acquired Rempex Pharmaceuticals for $140 million in cash up front, plus up to $214 million in development and regulatory milestones and $120 million in commercial milestones. Rempex is developing beta lactamase inhibitors...
BC Extra | Dec 5, 2013
Company News

Medicines Co. acquires antibiotic play Rempex

The Medicines Co. (NASDAQ:MDCO) acquired Rempex Pharmaceuticals Inc. (San Diego, Calif.) for $140 million in cash up front, plus up to $334 million in milestones. Rempex is developing beta lactamase inhibitors and antibiotics for multi-drug-resistant...
BioCentury | Oct 8, 2012
Emerging Company Profile

Fedora: Silver bullet against bugs

Fedora Pharmaceuticals Inc. aims to head off bacterial growth with beta lactamase inhibitors that are effective against all classes of the antibiotic resistance-conferring enzyme. The Canadian startup hopes to advance one of its lead compounds...
BC Week In Review | Sep 17, 2012
Clinical News

Rempex Pharmaceuticals preclinical data

In a nitrocefin degradation assay, which measures the kinetics of beta lactamase activity, RPX7009 inhibited Klebsiella pneumoniae carbapenemase-2 (KPC-2) with a Ki value of 0.071 µM, while clavulanic acid had a Ki value of 41.2...
BC Week In Review | Sep 17, 2012
Clinical News

Rempex Pharmaceuticals preclinical data

In a multi-drug resistant isolate panel of Enterobacteriaceae, the minimum inhibitory concentration with antimicrobial activity against 90% of the isolates (MIC90) was 0.5 µg/mL for Carbavance vs. >32 µg/mL for fluoroquinolones, aminoglycosides, cephalosporins, aztreonam and...
BC Week In Review | Sep 17, 2012
Clinical News

Rempex Pharmaceuticals preclinical data

In a mouse model of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumonia infection, Carbavance produced significantly lower bacterial counts in both lung and thigh infection models vs. RPX2003 alone. Carbavance is a combination of RPX7009, a...
BioCentury | Sep 17, 2012
Emerging Company Profile

Rempex Pharmaceuticals: No resisting

Many bacteria have developed resistance to carbapenems and efforts to combine those last-line antibiotics with drugs to restore bacterial sensitivity have been unsuccessful. Rempex Pharmaceuticals Inc. has designed a beta lactamase inhibitor that restored carbapenem...
Items per page:
1 - 10 of 12